Week 1 HW: Principles and Practices

Week 01 : Ethics and Principles

Ethics, safety, and security are key considerations throughout (and beyond!) this design process.
For Week 1, I use my project idea to think through how an engineered olfactory biosensor could be developed responsibly.

Class Assignment

1. Biological engineering application or tool

1. First, describe a biological engineering application or tool you want to develop and why. This could be inspired by an idea for your HTGAA class project and/or something for which you are already doing in your research, or something you are just curious about.

I am interested in engineering olfactory biosensors in E. coli that can detect specific odorant molecules and translate them into measurable outputs (fluorescence or an engineered scent). This connects directly to my background and upcoming internship in a sensory chemistry lab (ChemSenSim), where the focus is on understanding and simulating smell.

Motivation

• Scientific: Build sensors that “smell” defined odorants using genetic circuits (odorant receptor / odorant-binding module).
• Clinical: In the long term, such biosensors could contribute to standardized smell tests or detection of disease‑related compounds
• Ethical / practical: Bacterial sensors could reduce dependence on animals

Project trajectory (three aims)

• Aim 1 : Single‑odorant biosensor
  Design (and if feasible, assemble) a simple E. coli circuit that responds to one safe, well-characterized odorant with a reporter output (e.g. ATF1-based banana scent).

• Aim 2 : Combinatorial odor coding
  Extend the design to multiple odorants with distinct reporters, so combinations of odorants produce specific reporter patterns, ie the combinatorial coding of olfaction.

• Aim 3 : Disease‑linked sensing
  Conceptually explore biosensors that detect signatures associated with disease for potential clinical trials.

2. Governance / policy goals

2. Next, describe one or more governance/policy goals related to ensuring that this application or tool contributes to an “ethical” future, like ensuring non-malfeasance (preventing harm). Break big goals down into two or more specific sub-goals. Below is one example framework (developed in the context of synthetic genomics) you can choose to use or adapt, or you can develop your own. The example was developed to consider policy goals of ensuring safety and security, alongside other goals, like promoting constructive uses, but you could propose other goals for example, those relating to equity or autonomy.

For this project, I focus on three overarching governance goals, each split into sub‑goals:

2.1 Ensure biosafety of engineered olfactory E. coli

1. Prevent unintended environmental release of biosensor strains through appropriate strain choice, containment, and kill‑switches when needed.
2. Limit cross-contamination risks, specifcally repurposing sensors to monitor illicit substances or stigmatized health conditions without oversight.
3. Align with existing biosafety frameworks (NIH, WHO

2.2 Protect participants, lab workers, and the environment in odorant use

1. Use only non‑toxic, well‑characterized odorants with adapted toxicology knowledge.
2. Treat odorants and cultures with life‑cycle thinking: plan for safe waste treatment.
3. Educate researchers about odorant exposure risks.

2.3 Promote equitable, transparent, and clinically responsible use

1. Design population‑aware odor panels, recognizing that smell perception varies across populations
2. Protect olfactory privacy as HIPAA and RGPD Compliant sensitive health data requiring informed consent.
3. Communicate clearly with the public

3. Potential governance actions

3. Next, describe at least three different potential governance “actions” by considering the four aspects below (Purpose, Design, Assumptions, Risks of Failure & “Success”). Try to outline a mix of actions (e.g. a new requirement/rule, incentive, or technical strategy) pursued by different “actors” (e.g. academic researchers, companies, federal regulators, law enforcement, etc). Draw upon your existing knowledge and a little additional digging, and feel free to use analogies to other domains (e.g. 3D printing, drones, financial systems, etc.). Below, I describe three potential governance actions.

Option 1 : Odor‑Biosensor Biocontainment & Certification

Actors: Institutional Biosafety Committee, HTGAA teaching staff. 👌

• Purpose
  At present, many E. coli projects follow generic biosafety rules without specific guidance for whole‑cell biosensors that might interact with clinically relevant odorants or human samples.
  This action introduces a biosensor‑specific biocontainment and certification process, so that olfactory E. coli projects are reviewed with their particular risks in mind.

• Design

  • Define an approved strain and plasmid whitelist for teaching and exploratory biosensor work (non‑pathogenic E. coli K‑12 derivatives, minimized antibiotic resistance markers).
  • Require IBC registration for any constructs designed to respond to clinical VOCs or used with human-derived samples.
  • Couple certification with training modules specific to odor biosensing (handling volatile compounds, respiratory protection, odor exposure limits).

• Assumptions

  • Institutional committees have the time and expertise to evaluate biosensor projects.
  • Additional certification will not completely discourage student‑level innovation.
  • Genetic safeguards will be reliable enough for the scope of intended use.

• Risks of failure & “success”

  • Failure: The process becomes a bottleneck, discouraging exploratory student work or pushing experiments into unregulated DIY spaces.
  • Unintended success: Strong local certification may create an impression that biosensors are fully “safe” for clinical or commercial deployment before external regulators (e.g. FDA and ANSM) have weighed in.

Option 2 : In‑Silico Odorant Safety Screening & Standardized Panel

Actors: Sensory chemistry labs, toxicologists, researchers using odorants.

• Purpose
  Odorants for experiments are often chosen based on familiarity and convenience, with ad hoc toxicology checks. This action implements a computational pipeline and shared odorant panel to systematically select safe, representative stimuli for research and teaching.

• Design

  • Build a curated database of odorants with:
    • physico‑chemical properties,
    • perceptual descriptors,
    • toxicology and exposure limits, and
    • environmental fate where available.
  • Use machine learning and cheminformatics to propose panels of non‑toxic, diverse odorants suitable for lab use.
  • Publish standard operating procedures (SOPs) for preparation, serial dilutions, exposure protocols, and waste treatment.
  • Make the panel and SOPs open and versioned so that other labs can reuse and adapt them.

• Assumptions

  • Toxicology data are sufficiently complete for most common odorants.
  • A standardized panel will still leave room for exploratory work with new chemicals when justified.
  • Researchers will adopt shared tools when they clearly reduce preparation time and uncertainty.

• Risks of failure & “success”

  • Failure: Databases are incomplete or biased, leading either to false reassurance or unnecessary exclusion of promising odorants.
  • Unintended success: The standardized panel becomes a de facto global standard and unintentionally narrows the chemical search space, possibly overlooking disease‑relevant VOCs.

Option 3 : Clinical Framework for Olfactory Biosensor

Actors: Clinical collaborators, hospital ethics committees, patient organizations, PIs.

• Purpose
  Smell‑based biosensors can reveal sensitive health information (e.g., early signs of neurodegenerative disease) and might, in principle, detect behavioral or lifestyle markers. This action develops an ethical and clinical framework so that future translational work is guided.

• Design

  • Draft template informed‑consent language that explicitly addresses:
    • what information smell tests may reveal,
    • who will see the data, and
    • whether data may be reused or combined with other health records.
  • Require that any human‑facing pilot study with olfactory biosensors undergo review, regardless of perceived minimal risk.
  • Work with communications teams to create public‑facing explanations (webpages, leaflets) about how bacterial smell tests work, what they cannot infer, and which safeguards exist.

• Assumptions

  • Smell‑based biomarkers will be strong enough to raise privacy risks in at least some conditions.
  • Patients and the public will engage constructively if information is clear and honest.

• Risks of failure & “success”

  • Failure: An overly cautious framework slows down useful clinical validation or drives work to jurisdictions with weaker protections.
  • Unintended success: Heavy public emphasis on risks may stigmatize odor‑based diagnostics, making recruitment difficult even for low‑risk, high‑benefit applications.

4. Scoring governance actions

4. Next, score (from 1-3 with, 1 as the best, or n/a) each of your governance actions against your rubric of policy goals. The following is one framework but feel free to make your own:

Using the suggested rubric (1 = best / most effective, 3 = least effective, n/a = not applicable):

(1 = most effective / favorable; 3 = least; n/a = not applicable)

5. Prioritized governance options

5. Last, drawing upon this scoring, describe which governance option, or combination of options, you would prioritize, and why. Outline any trade-offs you considered as well as assumptions and uncertainties. For this, you can choose one or more relevant audiences for your recommendation, which could range from the very local (e.g. to MIT leadership or Cambridge Mayoral Office) to the national (e.g. to President Biden or the head of a Federal Agency) to the international (e.g. to the United Nations Office of the Secretary-General, or the leadership of a multinational firm or industry consortia). These could also be one of the “actor” groups in your matrix.

Audience: Potential clinical collaborators interested in olfactory diagnostics.

I would prioritize a combination of Option 1 and Option 2.

• Option 2 (Odorant Panel) is the fastest, lowest‑cost improvement. It directly supports lab safety and environmental protection.
• Option 1 (Certification) provides a clear institutional framework, ensures biosensor projects are back-controlled by safety committees.
• Option 3 (Ethics & Clinical Framework) becomes more important as the project moves from classroom experiments to clinical. Therefore, it might come useful on a longer time-frame.

Trade‑offs & uncertainties

• There is a tension between speed of innovation and depth of review: tighter certification and ethical review could slow creativity, especially for students, but may avoid larger problems later.
• Standardizing odorants improves safety and comparability but may restrict us from addressing some disease‑linked compounds.
• The predictive power of odor‑based biomarkers is still evolving despite governance.

Conclusion & Reflection

Working through this assignment made the project feel “real” to me. At first, teaching E. coli to “smell” was technically exciting to connect my interests in sensory chemistry and synthetic biology. Taking a step back and thinking about governance puts you into a hypothetical situation to see it as a potential diagnostic technology to interpret smell in people.

-> Several ethical concerns stood out this week:

• Olfactory privacy and identity. I had not considered directly that smell performance could become a new kind of biometric/health data. Once a bacterial sensor can distinguish disease states or behaviors, the line between a benign “smell test” and a sensitive diagnostic becomes very thin.

• Bias in what we choose to sense. Odor panels and diagnostic thresholds are not neutral. Choices about which odorants are “standard” could reflect particular cultures, and biosensors might reproduce those biases

• Replacing animals with engineered cells. I feel positively about reducing reliance on animals.

From these concerns, the governance actions that feel most realistic at this stage are: Treat smell-related data as health data by default, the same way data is handled throughout clinical trials in regard of HIPAA and RGPD Patient Protection.

References

might add those throughout the next courses !